Literature DB >> 17762036

Parkinson's disease.

C E Clarke1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17762036      PMCID： PMC1962892          DOI： 10.1136/bmj.39289.437454.AD

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  26 in total

1.  Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J M Miyasaki; W Martin; O Suchowersky; W J Weiner; A E Lang
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

2.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Authors: 
Journal:  Arch Neurol       Date:  2004-04

3.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

Authors:  C R Freed; P E Greene; R E Breeze; W Y Tsai; W DuMouchel; R Kao; S Dillon; H Winfield; S Culver; J Q Trojanowski; D Eidelberg; S Fahn
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

Authors:  Andrew J Hughes; Susan E Daniel; Yoav Ben-Shlomo; Andrew J Lees
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

5.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group.

Authors:  J Jankovic; A H Rajput; M P McDermott; D P Perl
Journal:  Arch Neurol       Date:  2000-03

6.  Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.

Authors:  A J Lees; R Katzenschlager; J Head; Y Ben-Shlomo
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

7.  Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.

Authors:  Dag Nyholm; Håkan Askmark; Cecilia Gomes-Trolin; Tina Knutson; Hans Lennernäs; Christer Nyström; Sten-Magnus Aquilonius
Journal:  Clin Neuropharmacol       Date:  2003 May-Jun       Impact factor: 1.592

Review 8.  Systematic review of paramedical therapies for Parkinson's disease.

Authors:  Katherine H O Deane; Caroline Ellis-Hill; Diana Jones; Renata Whurr; Yoav Ben-Shlomo; E Diane Playford; Carl E Clarke
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

9.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

Review 10.  Amantadine for dyskinesia in Parkinson's disease.

Authors:  N J Crosby; K H O Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  25 in total

1.  The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease.

Authors:  Beth E Fisher; Allan D Wu; George J Salem; Jooeun Song; Chien-Ho Janice Lin; Jeanine Yip; Steven Cen; James Gordon; Michael Jakowec; Giselle Petzinger
Journal:  Arch Phys Med Rehabil       Date:  2008-06-13       Impact factor: 3.966

Review 2.  Opicapone: A Review in Parkinson's Disease.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

3.  The nutritional status of Dutch elderly patients with Parkinson's disease.

Authors:  J van Steijn; B van Harten; E Flapper; E Droogsma; P van Walderveen; M Blaauw; D van Asselt
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

Review 4.  Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.

Authors:  Mark Sanford; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

Review 5.  Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Authors:  Paul L McCormack
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

6.  Rasagiline: a guide to its use in Parkinson's disease.

Authors:  Gillian M Keating; Katherine A Lyseng-Williamson; Sheridan M Hoy
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

7.  Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.

Authors:  Wenjia Zhou; Chengzhe Lv; Quanying Zhang; Shunlin Zong; Meng Wang
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 8.  Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

Authors:  Thomas Kramer; Fabio Lo Monte; Stefan Göring; Ghislaine Marlyse Okala Amombo; Boris Schmidt
Journal:  ACS Chem Neurosci       Date:  2012-01-18       Impact factor: 4.418

9.  Reversible parkinsonism due to a large intracranial tumour.

Authors:  Helena Rocha; António Cerejo; Maria Carolina Garrett; João Massano
Journal:  BMJ Case Rep       Date:  2012-12-23

Review 10.  Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.